This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARIA Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ariad Pharmaceuticals Stock (NASDAQ:ARIA) 30 days 90 days 365 days Advanced Chart Get Ariad Pharmaceuticals alerts:Sign Up Key Stats Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More… Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARIA Stock News HeadlinesResolution Therapeutics Announces £63.5 Million Series B Financing and Chair AppointmentOctober 3, 2024 | finance.yahoo.comSolu Therapeutics Strengthens Leadership Team with Appointment of Sergio Santillana, MD, as Chief Medical OfficerSeptember 10, 2024 | finance.yahoo.comElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.May 14, 2025 | Banyan Hill Publishing (Ad)Affimed Appoints Shawn Leland As New CEOSeptember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Finance Chief Vignola LeavingJuly 29, 2024 | marketwatch.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 27, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 12, 2024 | finance.yahoo.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 8, 2024 | msn.comSee More Headlines ARIA Stock Analysis - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) issued its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The firm's revenue was up 133.0% compared to the same quarter last year. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Meta Platforms (META), Bristol-Myers Squibb (BMY), Twitter (TWTR), ACADIA Pharmaceuticals (ACAD), Ford Motor (F) and Gilead Sciences (GILD). Company Calendar Last Earnings7/28/2016Today5/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ARIA CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ARIA) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ariad Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.